OliX Pharmaceuticals, Inc. engages in the research and development of treatments and the manufacture and sale of new drugs. It develops acid-based therapeutics based on ribonucleic acid interference (RNAi) technology. It offers hypertrophic scar treatments, subretinal fibrosis treatments, rod-cone dystrophy treatments, age-related macular degeneration products, and others. The company was founded by Dong-Ki Lee on February 26, 2010 and is headquartered in Suwon-si, South Korea.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company